drugset / Trial / NCT07623577
Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, multi-center phase II study to evaluate the safety and efficacy Sacituzumab Tirumotecan (Sac-TMT) plus bevacizumab in triple-negative breast cancer patients with brain metastases. Twenty-four participants are planned to be enrolled. The eligible patients should have histologically or cytologically confirmed TNBC with BM.
Timeline
- Start
- 2026-01-01
- Primary completion
- 2027-01
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | — |
| Subject | Sacituzumab Tirumotecan | Other / unclassified | 4 mg/kg | — |